FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approved a supplemental application for Singulair (montelukast) by Organon LLC. The action updates labeling under NDA020829.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Exercise-induced Bronchoconstriction
• Perennial Allergic Rhinitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• SINGULAIR (montelukast)

Snippet

SUPPL AP for SINGULAIR (MONTELUKAST SODIUM)